Enzon Stock Hits New 52-Week Low (ENZN)

NEW YORK ( TheStreet) -- Enzon Pharmaceuticals (Nasdaq: ENZN) hit a new 52-week low Wednesday as it is currently trading at $9.92, below its previous 52-week low of $9.93 with 59,540 shares traded as of 10:26 a.m. ET. Average volume has been 403,700 shares over the past 30 days.

Enzon has a market cap of $541.6 million and is part of the health care sector and drugs industry. Shares are down 17.9% year to date as of the close of trading on Tuesday.

Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for patients with cancer primarily in the United States and Europe. Its drug development program utilizes Customized Linker technology and the Locked Nucleic Acid technology.
  • Practice your ENZN trading strategies and win cash in our stock game.

TheStreet Ratings rates Enzon as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full Enzon Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing